Shearman & Sterling advised the lenders on a debt financing facility for Cinven’s acquisition of a majority stake in BioAgilytix (BALX Holdings, LLC). The credit facilities included term loans provided on the closing date and a delayed draw term loan facility. Cobepa, S.A., a Brussels-based private investment firm, remains a significant minority investor in the company.
BioAgilytix is a leading contract research organization specializing in large molecule needs, enabling scientific innovators to develop and deliver game-changing biologic innovations through our expertise in cell-based assays, biomarkers, immunogenicity and pharmacokinetics (PK).
Cinven is a private equity firm specializing in investments in buyouts, secondary, carve-out, growth capital, new market expansion, business roll-outs and industry consolidation. Its funds invest in six key sectors: Business Services, Consumer, Financial Services, Healthcare, Industrials and Technology, Media and Telecommunications (TMT).
The Shearman & Sterling team below included associates Kartika Pillay, Kevin Finkelstein (both NY-Finance), Anthony J. Roselle (NY-Real Estate) and Jacquelyn Watson (NY-ERISA).